Profile
Thomas R.
Ulich worked as an Executive Vice President-Research & Development at ConjuChem Biotechnologies, Inc. from 2006 to 2010, Senior Vice President-Research & Development at Alnylam Pharmaceuticals, Inc. in 2003-2004, and VP-Preclinical Development & Protein Therapeutics at Amgen Canada, Inc. from 1993 to 2001.
He was also a Professor at Wayne State University and the University of California, Berkeley.
Ulich's education includes an undergraduate degree from Dartmouth College and a doctorate from the David Geffen School of Medicine.
Former positions of Thomas R. Ulich
| Companies | Position | End |
|---|---|---|
| INVIVO THERAPEUTICS HOLDINGS CORP. | Chief Tech/Sci/R&D Officer | 2017-08-29 |
ConjuChem Biotechnologies, Inc. /Old/
 ConjuChem Biotechnologies, Inc. /Old/ Pharmaceuticals: MajorHealth Technology ConjuChem Biotechnologies, Inc. develops peptide based pharmaceuticals to treat diseases such as congestive heart failure, diabetes, HIV/AIDS and human growth deficiencies. The company is a research and development company that develops technology that binds peptides to albumin in order to extend the half life of drugs from minutes to days. ConjuChem Biotechnologies is headquartered in Montréal , Canada. | Chief Tech/Sci/R&D Officer | 2009-12-31 |
| ALNYLAM PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 2003-12-31 |
Amgen Canada, Inc.
 Amgen Canada, Inc. BiotechnologyHealth Technology Amgen Canada, Inc. operates as a biotechnology company. The company was founded in 1991 and is headquartered in Mississauga, Canada. | Chief Tech/Sci/R&D Officer | 2000-12-31 |
ConjuChem Biotechnologies, Inc.
 ConjuChem Biotechnologies, Inc. Pharmaceuticals: MajorHealth Technology ConjuChem Biotechnologies, Inc. develops peptide based pharmaceuticals. Its peptide products are used to treat diseases such as congestive heart failure, diabetes, HIV/AIDS and human growth deficiencies. ConjuChem Biotechnologies is a research and development company that develops technology that binds peptides to albumin in order to extend the half life of drugs from minutes to days. The company was founded on August 25, 2009 and is headquartered in Montréal, Canada. | Chief Tech/Sci/R&D Officer | - |
Training of Thomas R. Ulich
| Dartmouth College | Undergraduate Degree |
| David Geffen School of Medicine | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| ALNYLAM PHARMACEUTICALS, INC. | Health Technology |
| INVIVO THERAPEUTICS HOLDINGS CORP. | Health Technology |
| Private companies | 3 |
|---|---|
ConjuChem Biotechnologies, Inc. /Old/
ConjuChem Biotechnologies, Inc. /Old/ Pharmaceuticals: MajorHealth Technology ConjuChem Biotechnologies, Inc. develops peptide based pharmaceuticals to treat diseases such as congestive heart failure, diabetes, HIV/AIDS and human growth deficiencies. The company is a research and development company that develops technology that binds peptides to albumin in order to extend the half life of drugs from minutes to days. ConjuChem Biotechnologies is headquartered in Montréal , Canada. | Health Technology |
ConjuChem Biotechnologies, Inc.
ConjuChem Biotechnologies, Inc. Pharmaceuticals: MajorHealth Technology ConjuChem Biotechnologies, Inc. develops peptide based pharmaceuticals. Its peptide products are used to treat diseases such as congestive heart failure, diabetes, HIV/AIDS and human growth deficiencies. ConjuChem Biotechnologies is a research and development company that develops technology that binds peptides to albumin in order to extend the half life of drugs from minutes to days. The company was founded on August 25, 2009 and is headquartered in Montréal, Canada. | Health Technology |
Amgen Canada, Inc.
Amgen Canada, Inc. BiotechnologyHealth Technology Amgen Canada, Inc. operates as a biotechnology company. The company was founded in 1991 and is headquartered in Mississauga, Canada. | Health Technology |
- Stock Market
- Insiders
- Thomas R. Ulich
